top of page
Search

Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients

  • Writer: Rita L
    Rita L
  • Aug 10, 2020
  • 1 min read

Immunotherapy with immune checkpoint inhibitors for non-small cell lung cancer (NSCLC) has emerged as an important treatment option. Although immunotherapy may significantly improve survival and quality of life, response rates are as low as 20% in NSCLC patients.





 
 
 

Comments


© 2020 Konnet (Asia) Ltd. All Rights Reserved.

bottom of page